Loading organizations...
§ Venture Capital · San Francisco, CA, USA
Key people at Red Tree Venture Capital.
Red Tree Venture Capital operates as an early-stage life science venture firm, specializing in fostering innovation. The firm deploys a targeted strategy by leveraging its extensive relationships within the life sciences ecosystem. It primarily focuses on identifying and supporting emerging life science technologies that originate from premier academic and research institutions across the West Coast of the United States.
The firm was established in 2020 by Heath Lukatch, Ph.D., and Jennifer Cochran, Ph.D. Both founders bring considerable experience from the life science industry, which informed their vision for Red Tree. Their shared insight was to create a venture capital entity deeply integrated with institutional research, aiming to bridge the gap between groundbreaking academic discoveries and their commercial application.
Red Tree Venture Capital strategically invests in companies rooted in or connected to leading West Coast institutions, focusing on various stages from seed to later-stage development. The firm’s commitment is to nurture scientific advancements, guiding innovative life science ventures towards impactful realization for the broader scientific and medical communities. The long-term vision centers on cultivating a robust portfolio that drives significant progress in life sciences.
Red Tree Venture Capital is an early-stage life science venture capital firm focused on investing in transformative biotech and medical device companies primarily on the U.S. West Coast. Their mission centers on partnering with pioneering entrepreneurs to develop first-in-class or best-in-class therapeutics in oncology, neurology, and immunology, leveraging deep relationships with leading academic and research institutions such as Stanford and UC Berkeley. The firm raised $272 million in its inaugural fund in 2022 and emphasizes translating scientific innovation into successful businesses, positioning itself as a key partner for West Coast life science startups[1][2][4].
Founded in 2020 by Stanford researcher Jennifer Cochran and life science veteran Heath Lukatch, Red Tree was created to serve as a West Coast counterpart to Boston’s established biotech venture funds. The firm has expanded its footprint from the San Francisco Bay Area to San Diego, another major biotech hub, to tap into a broader innovation ecosystem. Early successes include backing companies like Cargo Therapeutics, which went public in 2025, demonstrating Red Tree’s ability to identify and support promising science-driven ventures from seed stages onward[2][3].
Red Tree is riding the wave of increasing biotech innovation concentrated on the U.S. West Coast, a region historically overshadowed by Boston’s biotech dominance. By focusing on early-stage life science ventures, especially in high-impact therapeutic areas, Red Tree capitalizes on the growing demand for novel treatments in oncology, neurology, and immunology. The firm’s timing aligns with a surge in biotech entrepreneurship and funding, as well as advances in scientific research at leading universities. Their expansion into San Diego further embeds them in a vibrant ecosystem, amplifying their influence on the West Coast biotech landscape[2][4].
Looking ahead, Red Tree is poised to continue scaling its impact through subsequent funds, such as its recently closed Fund II with $133 million raised, and by deepening its presence across West Coast biotech hubs. Trends shaping their journey include the increasing convergence of cutting-edge science and venture capital, the rise of precision medicine, and growing investor appetite for early-stage life science innovation. Red Tree’s influence is likely to grow as it nurtures more startups from inception to commercialization, potentially becoming a leading force in shaping the future of biotech innovation on the West Coast[7][1][2].
Key people at Red Tree Venture Capital.
Red Tree Venture Capital has more than 26 tracked investments across 21 companies. The latest tracked deal is $70.0M Series A in Excellergy in October 2025.
